Denmark will start putting patients suffering from type 2 diabetes on cheaper drugs before prescribing so-called GLP-1 drugs such as Novo Nordisk's Ozempic, the Danish Medicines Agency said on Wednesday. In 2023, 50% of new patients suffering from type 2 diabetes began treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first, the Medicines Agency said. Demand for Novo Nordisk's diabetes drug Ozempic has soared as many people have started using the diabetes drug for its weight-loss effects.
GLP-1 drugs (Ozempic and Mounjaro) could change shopping patterns in categories besides food. But in blocking our natural urge to consume, do we lose connection?
GLP-1 drugs (Ozempic and Mounjaro) could change shopping patterns in categories besides food. But in blocking our natural urge to consume, do we also lose connection?